UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A mutational hotspot that determines highly repeatable evolution can be built and broken by silent genetic changes

Nature communications, 2021-10, Vol.12 (1), p.6092-6092, Article 6092

2021

Volltextzugriff (PDF)

Mutational hotspots lead to robust but suboptimal adaptive outcomes in certain environments

Microbiology (Society for General Microbiology), 2023-10, Vol.169 (10)

2023

Volltextzugriff (PDF)

Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

BMC cancer, 2019-06, Vol.19 (1), p.582-10, Article 582

2019

Volltextzugriff (PDF)

MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

BMJ open, 2021-03, Vol.11 (3), p.e046225-e046225

2021

Volltextzugriff (PDF)

Effects of clusterin over-expression on metastatic progression and therapy in breast cancer

BMC cancer, 2010-03, Vol.10 (1), p.107-107, Article 107

2010

Volltextzugriff (PDF)

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

BMC cancer, 2019-11, Vol.19 (1), p.1102-9, Article 1102

2019

Volltextzugriff (PDF)

Readmission to hospital following laparoscopic cholecystectomy: a meta-analysis

Anaesthesiology intensive therapy : official publication of the Polish Society of Anaesthesiology and Intensive Therapy, 2020-01, Vol.52 (1), p.47-55

2020

Volltextzugriff (PDF)

CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial

Trials, 2020-01, Vol.21 (1), p.89-89, Article 89

2020

Volltextzugriff (PDF)

The Case for a More Holistic Approach to Dry Eye Disease: Is It Time to Move beyond Antibiotics?

Antibiotics (Basel), 2019-06, Vol.8 (3), p.88

2019

Volltextzugriff (PDF)

Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization

Oncogene, 2003-09, Vol.22 (41), p.6408-6423

2003

Volltextzugriff (PDF)

A meta-analysis of the use of intraoperative cholangiography; time to revisit our approach to cholecystectomy?

Surgery open science, 2021-01, Vol.3, p.8-15

2021

Volltextzugriff (PDF)

Glycerol Monolaurate Inhibits Lipase Production by Clinical Ocular Isolates Without Affecting Bacterial Cell Viability

Investigative ophthalmology & visual science, 2016-02, Vol.57 (2), p.544-550

2016

Volltextzugriff (PDF)

The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

Trials, 2020-10, Vol.21 (1), p.826-826, Article 826

2020

Volltextzugriff (PDF)

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial

The Lancet. Haematology, 2016-12, Vol.3 (12), p.e572-e580

2016

Volltextzugriff (PDF)

Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses

Cancers, 2023-01, Vol.15 (3), p.667

2023

Volltextzugriff (PDF)

Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node‐negative breast cancer patients

The FEBS journal, 2015-09, Vol.282 (18), p.3455-3473

2015

Volltextzugriff (PDF)

Targeting regulatory T cells to improve vaccine immunogenicity in early life

Frontiers in microbiology, 2014-09, Vol.5, p.477-477

2014

Volltextzugriff (PDF)

Human Epidermal Growth Factor Receptor 2 Testing by Fluorescent In Situ Hybridization: Positive or Negative? ASCO/College of American Pathologists Guidelines 2007, 2013, and 2018

Journal of clinical oncology, 2018-12, Vol.36 (35), p.JCO1800788-3523

2018

Volltextzugriff (PDF)

Dry eye disease: an (in)convenient truth

Clinical and experimental optometry, 2022-03, Vol.105 (2), p.222-229

2022

Volltextzugriff (PDF)

Human Epidermal Growth Factor Receptor 2 Testing by Fluorescent In Situ Hybridization: Positive or Negative? American Society of Clinical Oncology/College of American Pathologists Guidelines 2007, 2013, and 2018

Archives of pathology & laboratory medicine (1976), 2019-04, Vol.143 (4), p.412-413

2019

Volltextzugriff (PDF)

Diverse mutational routes to the restoration of motility in a soil bacterium

Access microbiology, 2020-07, Vol.2 (7A)

2020

Volltextzugriff (PDF)

Assessing the impact of the 2018 American Society of Clinical Oncology/College of American Pathologists recommendations on human epidermal growth factor receptor 2 testing by fluorescence in situ hybridization in breast carcinoma

Virchows Archiv : an international journal of pathology, 2020-03, Vol.476 (3), p.367-372

2020

Volltextzugriff (PDF)

SELIMETRY-a multicentre I-131 dosimetry trial: a clinical perspective

British journal of radiology, 2017-05, Vol.90 (1073), p.20160637-20160637

2017

Volltextzugriff (PDF)

Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

Blood, 2019-11, Vol.134 (Supplement_1), p.5552-5552

2019

Volltextzugriff (PDF)

1 – 25 von 176

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(158)
Mit Volltextzugriff
(145)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(109)
Life Sciences & Biomedicine
(95)
Humans
(72)
Female
(40)
Male
(22)
Breast Cancer
(18)
Oncology
(17)
Adult
(16)
Animals
(14)
Clinical Trials
(12)
Multidisciplinary Sciences
(12)
Mutation
(12)
Science & Technology - Other Topics
(12)
Tumors
(12)
Infant
(11)
Infant, Newborn
(11)
Medical Research
(11)
Middle Aged
(11)
Vaccination
(11)
Breast Neoplasms - Genetics
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(15)
Plos One
(6)
Endocrinology
(5)
The Lancet Regional Health. Europe
(5)
Bmj Open
(4)
British Journal Of Haematology
(4)
Canadian Medical Association Journal
(4)
Journal Of Clinical Oncology
(4)
Nature Communications
(4)
Bmc Cancer
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A mutational hotspot that determines highly repeatable evolution can be built and broken by silent genetic changes

Mutational hotspots lead to robust but suboptimal adaptive outcomes in certain environments

Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

Effects of clusterin over-expression on metastatic progression and therapy in breast cancer

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

Readmission to hospital following laparoscopic cholecystectomy: a meta-analysis

CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial

The Case for a More Holistic Approach to Dry Eye Disease: Is It Time to Move beyond Antibiotics?

Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization

A meta-analysis of the use of intraoperative cholangiography; time to revisit our approach to cholecystectomy?

Glycerol Monolaurate Inhibits Lipase Production by Clinical Ocular Isolates Without Affecting Bacterial Cell Viability

The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial

Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses

Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node‐negative breast cancer patients

Targeting regulatory T cells to improve vaccine immunogenicity in early life

Human Epidermal Growth Factor Receptor 2 Testing by Fluorescent In Situ Hybridization: Positive or Negative? ASCO/College of American Pathologists Guidelines 2007, 2013, and 2018

Dry eye disease: an (in)convenient truth

Human Epidermal Growth Factor Receptor 2 Testing by Fluorescent In Situ Hybridization: Positive or Negative? American Society of Clinical Oncology/College of American Pathologists Guidelines 2007, 2013, and 2018

Diverse mutational routes to the restoration of motility in a soil bacterium

Assessing the impact of the 2018 American Society of Clinical Oncology/College of American Pathologists recommendations on human epidermal growth factor receptor 2 testing by fluorescence in situ hybridization in breast carcinoma

SELIMETRY-a multicentre I-131 dosimetry trial: a clinical perspective

Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

Suchergebnisse filtern